AlzChem Committed to Digitalization and Artificial Intelligence (AI)
AlzChem is repositioning itself digitally. Together with the renowned company Sybit, an SAP Platinum Partner and Top 20 digital agency in Germany, our company is developing solutions for customer-oriented sales. The broad spectrum of AlzChem Group AG that ranges from nutrition, renewable energies, fine chemicals and agriculture to metallurgy and pharmaceuticals requires a comprehensive, homogeneous and error-free database. AlzChem and Sybit worked together on a project for six months that was aimed at using SAP Sales Cloud to install uniform sales templates, accelerate internal processes and ensure a homogeneous approach to customers. The focus here is on the customer, to whom the workflows, documentation and most important information are tailored.
In more specific terms, a new quotation process including a flexibly applicable quotation form was implemented that significantly increases the efficiency of quotation creation. The data quality has increased enormously thanks to a complex interface with the SAP ERP system and an automatic duplicate check.
In the area of e-mail and telephone communication, transparency and cross-platform services ensure easier organization, in the field, for example. Central management of data has already led to significantly improved efficiency in sales. For example, the mobile application of the SAP Sales Cloud brings major benefits, especially for field sales in the agricultural sector. AlzChem’s marketing also benefits from the SAP Sales Cloud that has enabled the first campaigns with KPI measurement.
“At AlzChem, we are always striving to improve both the efficiency of our processes and the satisfaction of our customers, and to take full advantage of a modern IT landscape. To this end, a CRM system constitutes an important building block for using the added value of a shared knowledge base and the application possibilities of artificial intelligence to better address specific customer needs,” said Michael Hilger from the IT department.
AlzChem also has other projects underway in which existing processes are being analyzed and optimized through the use of artificial intelligence and machine learning. Very good results have already been achieved and, in addition to a better understanding of the process, higher process yields and product quality have also been obtained.
Contact
Sabine Sieber
Head of Corporate Communications & Investor Relations
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
About Alzchem
Alzchem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. Alzchem benefits in particular from the three very different global developments of climate change, population growth and longer life expectancy. In order to achieve the resulting social goals, Alzchem products can offer attractive solutions with a wide range of different applications.
The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.
The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company’s response to global trends and developments. Alzchem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments.
The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2020, Alzchem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.